Up to 30% Better Glucose Control from Continuous Monitoring with Dexcom

Where the 30 percent figure comes from

Dexcom markets the G7 as producing up to 30 percent better glucose control than fingerstick testing, and that number traces to randomized trials in adults with type 2 diabetes managed on basal insulin. In those trials, participants assigned to continuous monitoring spent roughly 10 to 15 percentage points more time in the 70 to 180 mg/dL range than participants who tested with fingersticks, and their A1c ran about 0.3 to 0.5 percentage points lower at six months. The 30 percent figure is a relative reduction in one outcome measure; it does not translate into 30 additional points of time in range.

Population selection shapes the result. Every one of those trials enrolled people with a diabetes diagnosis, most of them using insulin or a sulfonylurea, so the comparison group carried a measurable baseline risk of hypoglycemia. Someone tracking glucose for general wellness has no equivalent baseline, and the same relative improvement applied to readings that already sit inside the reference range produces a much smaller absolute change. No trial has measured whether that smaller change alters any health outcome.

The filament, the interstitial fluid, and the lag

A thin filament sits in subcutaneous fat, usually on the back of the upper arm, and it is the only part of the Dexcom G7 that touches biology. The filament surface carries glucose oxidase, an enzyme that oxidizes glucose to gluconolactone and hydrogen peroxide. The peroxide is oxidized at a platinum electrode, and the resulting current is proportional to the glucose concentration in the surrounding fluid. The transmitter samples that current on a fixed interval and converts it into the number on the screen.

Dexcom samples interstitial fluid, not blood. Glucose moves from capillaries into the interstitial space by diffusion, which takes time. That lag runs 5 to 15 minutes. At steady state the two compartments track closely, and the difference is small. During rapid change the interstitial reading trails capillary blood, which is why a fingerstick taken at the peak of a fast rise can disagree with the sensor by 30 mg/dL or more while both readings are correct.

Accuracy is reported as mean absolute relative difference, or MARD. Dexcom G7 warms up in 30 minutes. Dexcom’s pivotal studies for the G7 put adult MARD in the range of roughly 8 to 9 percent, and MARD is a mean, so individual readings scatter more widely than the summary figure suggests. Accuracy is also weakest in the first hours after insertion, when the tissue around the filament is still responding to the trauma of placement.

Lying on the sensor arm compresses local capillaries, reduces perfusion, and the algorithm reads the drop in current as falling glucose. The result is a false low that appears in overnight traces and resolves within minutes of changing position. A reading below 70 mg/dL that arrives without a matching trend arrow and disappears on the next sample is usually this artifact.

Chemical interference in Dexcom sensors is narrower than it was in the G4 generation. The G4 and G5 required users to avoid acetaminophen because the drug’s oxidation potential overlapped with that of hydrogen peroxide at the electrode. The G6 removed that restriction. The G7 kept that design.

The number on the screen is a processed value, not a raw current measurement. Dexcom smooths the signal. The trend arrow is a separate estimate of rate of change computed over a rolling window. During the lag window the arrow carries more information than the absolute number, because it indicates where the interstitial value is heading while the blood value has already moved.

Sleep, cortisol, and the morning rise

Between roughly 2 and 8 am, growth hormone and cortisol both rise, hepatic glucose output increases, and peripheral insulin sensitivity dips. That sequence produces the dawn phenomenon, a morning glucose rise that CGM makes visible in people who have never seen their own overnight trace. The magnitude is smaller in people without diabetes, but the shape is the same.

Sleep duration changes glucose handling within three nights of restriction. A study published in PNAS in 2008 suppressed slow-wave sleep in healthy young adults across three nights and measured a reduction in insulin sensitivity with no change in total sleep time. Earlier work in The Lancet restricted healthy men to four hours in bed for six nights and found glucose tolerance had fallen. Both results came from controlled laboratory protocols with small samples, and both point at one mechanism: sleep loss raises evening cortisol and shifts the balance between glucose appearance and disposal.

Fragmented sleep produces a different overnight pattern. Repeated arousals and intermittent hypoxia from obstructive sleep apnea raise sympathetic activity, and the trace shows a sawtooth of small rises across the night. Continuous positive airway pressure reduces nocturnal glucose excursions in adults with diagnosed apnea, though the effect on daytime A1c is smaller than the overnight change would suggest.

Dexcom Stelo and the over-the-counter tier

Dexcom received FDA clearance for Stelo in March 2024, the first over-the-counter glucose biosensor sold in the United States. Stelo wears for 15 days, reports a value every five minutes, and carries no alarms, which separates it from the prescription G7. It is cleared for adults who do not use insulin, the group the 30 percent trial data does not cover.

Exercise changes the reading before it changes the trend

Contraction of skeletal muscle moves GLUT4 transporters to the cell membrane without insulin signaling. That pathway is why moderate aerobic work lowers glucose during the session, and why a walk started within an hour of a meal flattens the postprandial peak. Ten to twenty minutes of walking usually shifts the trace.

Hard intervals run the other direction in the first 20 minutes. Catecholamines and glucagon rise, the liver releases glucose, and the reading climbs before falling as muscle uptake catches up. Resistance training with short rest periods produces a similar early rise in many people. The window after the session is where the effect reverses: insulin sensitivity stays elevated for many hours, sometimes into the following day, and the same meal produces a smaller excursion than it did the day before.

Timing the session against the trace is the practical use of the sensor here. A pre-breakfast walk changes a fasting reading differently than a post-dinner walk changes a postprandial peak, and the two effects land on different parts of the daily curve.

Glucose variability as a target without a diagnosis

Clinicians summarize short-term glucose stability with the coefficient of variation, the standard deviation of readings divided by the mean glucose. An international consensus statement on time in range, published in 2019, set a target of 36 percent or lower for adults with diabetes. The threshold came from studies linking higher variability to hypoglycemia risk in insulin-treated populations.

Applying that number to people without diabetes is where the evidence thins. The 2019 consensus sets no target for them, and the underlying studies enrolled only insulin-treated adults. The most frequently cited dataset of healthy volunteers wearing CGM enrolled fewer than 60 participants over two weeks. PLOS Biology published it in 2019, and no larger cohort has replaced it.

Reference ranges for non-diabetic glucose drawn from datasets of that size have wide boundaries and poorly characterized tails. No randomized trial has tested whether reducing glucose variability in adults without diabetes changes the incidence of cardiovascular events, progression to type 2 diabetes, or mortality. The interventions that do carry outcome evidence in that population are weight reduction, blood pressure control, and sustained physical activity, none of which requires a sensor to detect.

The sensors will keep producing a reading every five minutes. What that reading should change in someone without a diagnosis is not yet established.